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Abstract
Introduction: The diagnostic algorithm of non-high risk pulmonary embolism (PE) is based on probability scoring systems and 
plasma D-dimer (DD) assessment. The aim of the present study was to investigate the efficacy of Revised Geneva Scoring (RGS) 
and DD testing for the excluding of non-high risk PE, in the patients admitted to the hospital due to acute respiratory diseases.
Material and methods: The consecutive patients, above 18 years of age, referred to the department of lung diseases, entered the 
study. The exclusion criteria were: the pregnancy and the suspicion of high risk PE. Plasma DD was measured with quick ELISA 
test, VIDAS D-dimer New, bioMerieux, France. Multislice computed tomography angiography was performed in all of the patients. 
Results: 153 patients, median age 65 (19−88) years entered the study. The probability of PE was: low — in 58 patients (38%), 
intermediate — in 90 (59%), high — in 5 (3%). DD < 500 ng/ml was found in 12% of patients with low and intermediate pro-
bability of PE. PE was recognized in 10 out of 153 patients (7%). None of the patients with DD < 500 ng/ml was diagnosed 
with PE (NPV 100%). Median DD value was significantly higher in PE patients comparing to non-PE (4500 ng/ml and 1356 ng/ml 
respectively, p = 0.006). 
Conclusion: In the group of the patients with acute respiratory symptoms, low or intermediate clinical probability scoring com-
bined with normal DD had a high NPV in excluding PE. Nevertheless, such approach was not very effective, as the increased DD 
was noted in 88% of the examined population. 
Key words: d-dimer, pulmonary embolism, probability assessment, respiratory diseases
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Introduction
Venous thromboembolic disease (VTE) is 
a common and potentially life threatening disease, 
with the incidence rate of 100–200/100 000 in 
Europe and in the United States of America [1, 2]. 
The risk factors, such as: previous episodes of deep 
vein thrombosis, immobilization, trauma, neoplastic 
disease, markedly increase the probability of VTE 
[3–5]. According to recent publications, incidence 
of VTE is also increased in the patients with chronic 
lung disorders, such as: chronic obstructive pulmo-
nary disease (COPD) [6], severe asthma [7], idiopa-
thic pulmonary fibrosis [8] and sarcoidosis [9, 10].
The diagnostic algorithm of non-high risk PE 
is based on probability scoring systems, such as 
Wells Score or Revised Geneva Score (RGS) [11]. In 
the patients with low and intermediate probability 
Pneumonologia i Alergologia Polska 2015, vol. 83, no. 6, pages 445–452 
446 www.pneumonologia.viamedica.pl
of PE, plasma D-dimer (DD) evaluation is the next 
diagnostic step, according to ESC guidelines [11]. 
The quantitative DD tests based on enzyme-linked 
immunosorbent assays are recommended for this 
procedure [11]. Normal D-dimer concentration (< 
500 ng/mL) in the patient with low or intermedia-
te probability of PE has high negative predictive 
value (NPV) for VTE [12]. The risk of PE deve-
lopment in such population is less than 1% in 3 
months of subsequent follow up [12]. 
DD is a non-specific marker indicating the ac-
tivation of the process of fibrin turnover. Elevated 
DD concentrations were reported in pregnancy, 
pneumonia, sepsis, Alzheimer’s disease, arterial 
thrombosis, and malignancy [13–15]. Moreover DD 
level correlates with age and increases in the patients 
above 50 years of age [16, 17]. Recently, Schouten et 
al. proposed the age adjusted DD cut off (age × 10 
ng/mL) [18]. The authors of the ADJUST-PE study 
found that age-adjusted DD threshold is combined 
with improvement of specificity without loosing of 
the sensitivity of the model of PE prediction based 
on clinical probability and DD [19]. Nevertheless, 
according to Woller et al. further validation is needed 
to finally approve such diagnostic approach [20]. 
Renal insufficiency may also influence DD concen-
tration, but the increase of DD in the patients with 
GRF 30–60 mL/min is moderate [21].
The value of PE diagnostic algorithm based 
on probability scoring and DD was not investi-
gated extensively in the patients with acute or 
exacerbated respiratory diseases. Thus the aim of 
the present study was to investigate the efficacy of 
RGS and DD testing for the excluding of non-high 
risk PE, in the patients admitted to the hospital 
due to acute respiratory symptoms.
Material and methods
The consecutive patients, above 18 years of 
age, referred in 2013 to the Ist Department of Lung 
Diseases of the National Institute of Tuberculosis 
and Lung Diseases in Warsaw due to acute respi-
ratory symptoms, entered the study. The exclusion 
criteria were: the pregnancy and the suspicion of 
high risk PE, based on the signs of shock or signifi-
cant hypotension defined as the decrease of systolic 
blood pressure to the value below 90 mm Hg or 
greater than 40 mm Hg, for at least 15 minutes [10].
The PE probability was assessed with RGS 
(Table 1). Plasma DD was measured in all of the 
patients, on 1–3 hospital day, with quick ELISA 
test, VIDAS D-dimer New, bioMerieux, France. 
Threshold value for DD was 500 ng/mL according 
to manufacturer’s recommendations.
Multislice computed tomography angio-
graphy (CTA) was performed in all of the patients 
with a 16-detector scanner (Siemens Somatom 
Sensation 16) according to “pulmonary embo-
lism” protocol. 80 mL of low osmotic, iodine 
contrast medium was used (intravenous injection, 
with an automatic syringe). 
The following clinical and laboratory pa-
rameters were recorded: dyspnea, chest pain, 
hemoptysis, cough, purulent expectoration, 
increased body temperature on admission (> 
38°C), morphological blood analysis, CRP, and 
blood gas analysis.
Statistical analysis
A database and all analyses were performed 
using STATISTICA 6.0 (Statsoft) computer softwa-
re. The results were expressed as median values 
and ranges. For comparison of categorical variab-
les between the groups — the Fisher test was used, 
for continuous variables — U Mann-Whitney and 
Kruskal-Wallis tests were applied. P-value < 0.05 
was considered statistically significant.
Results
153 patients (84 males and 69 females), 
median age 65 (19–88) years entered the study. 
Clinical characteristics of the study population 
is presented in Table 2. Most frequent complaints 
Table 1. Revised Geneva Scoring 
Variables Points
Predisposing factors
age > 65 years 1 
Previous DVT or PE 3
Surgery of fracture within one 
month
2
Active malignancy 2
Symptoms 
Unilateral lower limb pain 3
Hemoptysis 2
Clinical signs
Heart rate  
75 to 94 per minute  
≥ 95 per minute
 
3 
5
Pain on lower limb deep 
vein palpation or unilateral 
oedema 
4
Clinical probability Low: 0–3 point, intermediate: 
4–10 points, High: ≥ 11 points
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Table 2. Clinical characteristics of the examined population and comparison of PE and non-PE patients (pts) 
Clinical characteristics Total 
No 153
PE pts 
No 10
Non-PE pts 
No 143
P
PE vs. non PE
Age (median, range) 65.0 (19.0–88.0) 65.5 (43.0–81.0) 65.0 (19.0–88.0) 0.85
Gender males/females 84/69 (54.9/45.1%) 7/3 (70/30%) 77/66 (53.8/46.1%) 0.51
Dyspnea n (%) 111 (72.5) 8 (80.0) 103 (72.0) 0.73
Chest pain n (%) 38 (24.8) 5 (50.0) 33 (23.1) 0.12
Cough n (%) 107 (69.9) 6 (60.0) 101 (70.6) 0.49
Hemopthysis n (%) 31 (20.3) 2 (20.0) 29 (20.3) 1.0
Purulent sputum n (%) 24 (15.7) 0 (0.0) 24 (16.8) 0.36
Temp > 38°C 41 (26.8) 2 (20.0) 39 (27.3) 1.0
VTE med. hist. n (%) 15 (9.8) 3 (30.0) 12 (8.4) 0.06
Risk factors n (%) 35 (22.9) 3 (30.0) 32 (22.4) 0.7
Revised Geneva Score (median) 4 (0–11) 4.5 (0–11) 4.0 (0–11) 0.92
PE — pulmonary embolism; VTE — venous thromboembolic disease
were: dyspnea (72%) and cough (69.9%). Hemop-
tysis and pleuritic chest pain were found in 20% 
and 24.8% of patients respectively. 
RGS revealed low probability of PE — in 58 
patients (38%), intermediate probability — in 90 
(59%) and high probability — in 5 (3%). DD < 500 
ng/mL was found in 18 out of 148 patients with 
low and intermediate probability of PE (12%): in 
3/58 of patients with low probability of PE (5%) 
and in 15/90 of patients with intermediate pro-
bability of PE (16%). 
PE based on CTA was recognized in 10 out 
of 153 patients (7%): 4/58 (7%) of low probability 
population, 4/90 (4%) of intermediate probability 
and 2/5 (40%) of high probability. The thrombi 
were localized in lobar pulmonary arteries — (2 
patients), in segmental pulmonary arteries — (3 
patients), both lobar and segmental — pulmonary 
arteries — (4 patients), sub-segmental arteries (1 
patient). Radiological signs of lung infarcts and/
or pleural fluid were found in 2 patients. In 7 out 
of 10 PE patients other pathology was additio-
nally diagnosed: lung cancer — in 2 patients, 
pneumonia, COPD, sarcoidosis, idiopathic lung 
fibrosis and heart insufficiency — in 1 patient 
each.
The final diagnosis in those patients in whom 
PE was excluded was: neoplastic disease of the 
chest (lung cancer, thymoma, mesothelioma) — in 
45 patients (pts), community acquired pneumo-
nia (CAP) — in 18 pts, exacerbation of asthma or 
COPD — in 15 pts, idiopathic pulmonary fibrosis 
(IPF) — in 10 pts, other interstitial lung dise-
ase — in 19 pts, infective exacerbation of cystic 
fibrosis (CF) or non-CF bronchiectasis — in 11 
pts, organizing pneumonia (OP) or bronchiolitis 
obliterans (BO) — in 7 pts, heart failure — 3 pts, 
vasculitis — 4 pts, tuberculosis or non-tuberculo-
us mycobacterial lung disease (NTMLD) — 3 pts, 
other lung diseases — 8 pts.
The comparison of clinical characteristics 
of the group with PE and of the remaining pa-
tients (Table 2) revealed that VTE history was 
more frequent in the patients with PE comparing 
to non-PE (30% vs. 8.4%, p = 0.06). Purulent 
expectoration hasn’t been noted in PE, but it was 
also rarely recorded in the remaining patients 
(16.8%). Chest pain was more frequent in PE than 
in non-PE patients (50% vs. 23.1%), nevertheless 
the difference was not significant. Dyspnea, he-
moptysis and increased body temperature were 
reported with the same frequency in PE and non-
PE patients.
DD < 500 ng/mL was found in 18/153 patients 
(12%). None of the patients with DD < 500 ng/
mL was diagnosed with PE. The results of the 
diagnostic algorithm based on RGS, DD and CTA 
are shown on Figure 1. The diagnostic value of 
DD < 500 ng/mL for the exclusion of PE in low/
intermediate risk patients was high: sensitivity — 
100%, negative predictive value — 100%.
Median DD value in PE patients was 4500 
(525.0–5860.0) ng/mL and it was significantly 
higher than in the remaining patients, in whom 
median DD was 1356 (105.0–33935.0) ng/mL, p 
= 0.006. Elevated plasma DD was found in 135/ 
153 (88%) patients: in 10 patients it was observed 
in the course of PE episode, in the remaining pa-
tients — in the course of other lung pathologies 
listed in Table 3. 
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Table 3. D-dimer (DD) concentration according to clinical diagnosis
Diagnosis No of pts Median DD
[ng/ml]
Range
[ng/ml]
> 500 No(%)
[ng/ml]
P 
vs. PE
Neoplastic disease 45 1741.0 292.0–28144.0 41 (91) 0.03
Pneumonia + tuberculosis, NTMLD 21 1870.0 179.0–9266.0 19 (90) NS
COPD/astma 15 861.1 258–2825.24 11 (73) 0.001
IPF 10 780.45 257.58–1833.0 7 (70) 0.003
Other ILD 19 1089.0 268.0–5409.4 18 (95) 0.02
OP/BO 7 2194.0 1106.0–13201.0 7 (100) NS
CF, bronchiectasis 11 1177.0 169.0–33935.0 10 (91) 0.02
Hemopthysis, heart failure, others 11 723.0 105.0–4361.0 9 (82) 0.006
Vasculitis 4 3129.41 266.0–6467.0 3 (75) NS
PE 10 4500.0 525.0–5860.0 10 (100)
Total 153 1466.0 105.0–33935.0 135 (88)
NTMLD — nontuberculous mycobacterial lung disease; IPF — idiopathic pulmonary fibrosis; ILD — interstitial lung disease; OP — organizing pneumonia; BO — bron-
chiolitis obliterans; PE — pulmonary embolism; NS — non-significant
Figure 2. DD-values according to clinical diagnosis
Diseases: 1 — neoplastic disease; 2 — pneumonia, tuberculosis, 
nontuberculous mycobacterial lung disease; 3 — COPD, astma; 4 — 
idiopathic pulmonary fibrosis; 5 — other interstitial lung diseases; 6 
— organizing pneumonia, bronchiolitis obliterans; 7 — cystic fibrosis, 
bronchiectasis; 8 — hemoptysis, heart failure, others; 9 — vasculitis; 
10 — pulmonary embolism. P-values in Table 3
Figure 1. PE recognition based on Revised Geneva Scoring, D-dimer assessment and computed tomography angiography
The highest median DD values in non-PE 
patients were observed in the course of vasculitis 
(3129.4 ng/mL), OP/BO (2194 ng/mL), CAP (1870 
ng/mL), neoplastic disease (1741 ng/mL), infective 
exacerbation of CF or bronchiectasis (1177 ng/
mL), the lowest — in COPD/astma exacerbation 
and in IPF (Table 3, Figure 2). The statistical 
significance of the obtained results of DD in va-
rious lung diseases comparing to PE patients are 
presented in Table 3.
The comparison of the remaining laboratory 
parameters between the PE patients and groups 
with other lung diseases (Table 4) revealed that 
CRP value was significantly higher in CAP than in 
PE patients, median values were 135.4 ng/mL and 
34.46 ng/mL respectively (p < 0.03) (Figure 3).
Discussion
In the present study, PE based on CTA was 
recognized in 10 out of 153 patients (7%) with 
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acute respiratory symptoms: 7% of low PE probabi-
lity population, 4% of intermediate probability and 
40% of high probability. The frequency of PE in our 
material was slightly lower than reported in meta
-analysis of Ceriani et al., who found PE confirmed 
on CTA in 9% of low probability patients, 26% — of 
intermediate probability and 76% of high probability 
ones [22]. This difference could be possibly related 
to the patients characteristics. The population evalu-
ated by RGS in Ceriani’s study was composed of the 
outpatients and our population consisted of patients 
hospitalized due to acute lung disease. 
In our population, the algorithm of VTE 
probability assessment based on RGS and DD, 
had a high NPV (100%), as none of the patients 
with DD < 500 ng/mL and low or intermediate 
probability of PE, was diagnosed with PE. Ne-
vertheless, low DD was found only in 12% of 
patients with acute lung disease, therefore its 
clinical utility in this population was low. The 
same problem was noted by Fijałkowska et al., 
who analyzed 619 patients with both acute and 
chronic lung pathology and found DD elevation 
in 63% of patients [23]. Kline et al. found positi-
ve DD in 84% of patients hospitalized on medical 
and emergency wards with the suspicion of PE, 
and confirmed PE in 19% of patients only [24]. 
The increase of DD cut off value from 500 ng/mL 
to 1000 ng/mL, in the patients with RGS lower 
than 6 points, resulted in the improvement of 
diagnostic utility of such algorithm, nevertheless 
it was combined with the slightly increased risk 
of missing isolated sub-segmental PE [24]. In our 
group of patients the increase of DD threshold 
from 500 ng/mL to 1000 ng/mL would result in 
missing one PE case in the patient with inter-
mediate probability of PE.
In the present study, median DD in PE pa-
tients was 4500 ng/mL and it was significantly 
higher than in non-PE group. The same observa-
tion was made by Lippi et al. who found DD > 
3000 ng/mL indicative of VTE in the population 
of large urban emergency department [25].
The highest median DD values in non-PE 
lung diseases were observed by us in the course 
of vasculitis (3129.4 ng/mL), and in OP/BO (2194 
ng/mL). Nevertheless it is difficult to comment on 
this issue, as vasculitis was recognized in 4 pa-
tients only and OP/BO — in 7 patients. According 
to our best knowledge no other data concerning 
this subject has been published. 
The frequent cause of DD elevation in the pre-
sent study was the community acquired pneumo-
nia. Median DD concentration in CAP patients was 
1870 ng/mL, the difference between CAP and PE 
concerning DD value, was not significant. Milbrandt 
et al. assessed DD concentration (latex immunoas-
say, cut off value 256 ng/mL) in 934 patients hospi-
talized due to CAP and found DD elevation in 80.6% 
of them [26]. Moreover, no substantial changes of 
DD have been observed during the first 7 days of 
CAP treatment [26]. The authors suggested that 
local activation of coagulation, mediated by tissue 
factor (TF), was the cause of increased DD concen-
tration in pneumonia. The TF, expressed on alveolar 
macrophages, neutrophils and endothelial cells, 
might be responsible for systemic coagulopathy 
during lung infection. The authors found that DD 
elevation was a negative prognostic factor in CAP: 
DD 256–1000 ng/mL was combined with 2–3 fold 
higher mortality rate and DD > 1000 ng/mL — with 
5 fold higher mortality rate [26]. Snijders et al. and 
Agapakis et al. found DD concentration significantly 
higher in patients with severe CAP (CURB-65 score 
3–5) comparing to the others [27, 28]. 
The other frequent cause of DD elevation 
in our study was neoplastic disease of the chest 
(lung cancer, thymoma, mesothelioma). Median 
DD was 1741 ng/mL, the values were significan-
tly lower than in PE patients. Fijałkowska et al. 
found DD increase in the course of lung cancer 
in 75% of patients, with median value of 941 ng/
mL [23]. The histological type of neoplasm and 
the disease extension are probably influencing 
DD-concentration [23, 29].
Relatively lower DD values were found by us 
in the course of asthma or COPD exacerbation. 
Figure 3. CRP values according to clinical diagnosis
Diseases: 1 — neoplastic disease; 2 — pneumonia, tuberculosis, nontu-
berculous mycobacterial lung disease; 3 — COPD, astma; 4 — idiopathic 
pulmonary fibrosis; 5 — other interstitial lung diseases; 6 — organizing 
pneumonia, bronchiolitis obliterans; 7 — cystic fibrosis, bronchiectasis; 
8 — hemoptysis, heart failure, others; 9 — vasculitis; 10 — pulmonary 
embolism. P-value: 10 vs. 2 p = 0.03; 10 vs. 8 p = 0.03
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According to Sabit et al. hypoxia and systemic 
inflammation are responsible for pro-coaguable 
status in COPD, manifesting mainly as the in-
crease of thrombin-antithrombin complex, but 
not DD concentration [30]. Accordingly, Silva 
et al. found no difference in DD concentration 
between stable COPD patients and the control 
subjects [31]. The increase of DD concentration 
in COPD may be caused by infective exacerba-
tion. Nevertheless, data from literature indicate 
that VTE has been responsible for DD increase in 
5–38% of patients with COPD exacerbation [32, 
33]. Choi et al. found that DD ≥ 500 ng/mL and 
the absence of symptoms of respiratory infection, 
were the significant predictors of PE in the Korean 
patients with COPD exacerbation [32]. Fruchter 
et al. found that elevated DD was a reliable pro-
gnostic marker for those COPD patients in whom 
PE was excluded [34].
In our study, median DD in the patients dia-
gnosed with interstitial lung disease was 780.45 
ng/mL (IPF) and 1089 ng/mL (non-IPF), and they 
were significantly lower than in PE patients. 
There is not much data in literature concerning 
DD assessment in the patients with ILDs. Barga-
gli et al. found significantly increased DD in IPF 
comparing to the controls [35].
Increased DD in the course of ILDs exacer-
bation may suggest the PE occurrence. Luo et al. 
found PE in 26% of the patients with exacerbation 
of ILDs, the factors increasing the probability of 
PE were: dyspnea, palpitations, lower extremity 
edema, and positive D-dimer [36].
As in majority of the patients in our study PE 
could not be excluded based on RGS and DD, we 
tried to find whether the other clinical and/or labo-
ratory parameters would be helpful in predicting or 
excluding PE. The analysis of clinical parameters 
revealed that previous history of VTE was more 
frequent in PE patients. The remaining clinical 
features such as dyspnea and hemoptysis were not 
helpful in differential diagnosis. Pleuritic chest 
pain was more frequent in PE patients comparing 
to the others, but this difference was not significant. 
The analysis of laboratory parameters re-
vealed that CRP value was significantly higher 
in CAP comparing to PE. In contrast to general 
population, hypoxemia and hypocapnia, were 
not indicative for PE in the examined group of 
patients with acute respiratory symptoms. 
Conclusion
In the examined group of the patients with 
acute or exacerbated lung diseases low or inter-
mediate clinical probability scoring combined 
with normal DD (< 500 ng/mL) had a high NPV 
in excluding PE. Nevertheless, such approach was 
not very effective, as the increased DD (> 500 ng/
mL) was noted in 88% of the examined popula-
tion. Although median DD was the highest in PE 
patients, relatively high DD were found also in the 
course of vasculitis, OP/BO, CAP and neoplastic 
disease. The probability of PE was higher in the 
patients with previous history of VTE. High CRP 
was indicative of CAP.
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